Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumab

Antibody directed chemotherapy (ADC) takes advantage of the selectivity of the monoclonal antibody to increase the efficacy of the chemotherapeutic agent, while reducing toxicity. Previously we described three nab-paclitaxel (Abraxane) nanoparticles coated with commercial monoclonal antibodies. Iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Butterfield, John T., Kim, Hidong, Knauer, Daniel J., Nevala, Wendy K., Markovic, Svetomir N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670201/
https://www.ncbi.nlm.nih.gov/pubmed/29101359
http://dx.doi.org/10.1038/s41598-017-15251-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670201/
https://www.ncbi.nlm.nih.gov/pubmed/29101359
http://dx.doi.org/10.1038/s41598-017-15251-6

Ejemplares similares